



Oregon Prescription Drug Affordability Board

350 Winter Street NE, Salem, OR 97309-0405 | 971-374-3724 | pdab@dcbs.oregon.gov | dfr.oregon.gov/pdab

Agenda

This is a regular meeting. *Date: May 15, 2024 | Time: 9:30 a.m.*

This is a draft agenda and subject to change.

Meeting name	Prescription Drug Affordability Board	Board Members: Chair Shelley Bailey; Vice Chair Amy Burns; Daniel Hartung; Robert Judge; Christopher Laman; John Murray; Akil Patterson Staff: Ralph Magrish, executive director; Cortnee Whitlock, policy analyst; Stephen Kooyman, project manager; Melissa Stiles, administrative specialist; Jake Gill, counsel; Pramela Reddi, counsel
Meeting location	Virtual	
Zoom link	Register for the meeting	

Purpose	Subject	Presenter	Estimated Time Allotted
<i>Informational and vote</i>	Call to order, roll call, approval of 04/17/2024 minutes	Chair Bailey	5 minutes
<i>Informational</i>	Executive director's program update	Ralph Magrish	5 minutes
<i>Discussion and vote</i>	Board discussion and vote on the OAR 925-200-0010 status of Inflectra and Skyrizi	Chair Bailey	10 minutes
<i>Discussion</i>	Affordability review: 1) Ozempic: <ul style="list-style-type: none"> • Drug-specific public comment • Board discussion 	Ralph Magrish and Cortnee Whitlock	30 minutes including 20 minutes of public comment
<i>Discussion</i>	Affordability review: 2) Trulicity: <ul style="list-style-type: none"> • Drug-specific public comment • Board discussion 	Ralph Magrish and Cortnee Whitlock	30 minutes including 20 minutes of public comment
	5-minute break	Chair Bailey	5 minutes
<i>Discussion and vote</i>	Board consideration of and vote on generic drug report prepared for the Oregon Legislature	Cortnee Whitlock	10 minutes
<i>Discussion</i>	Senate Bill 192 upper payment planning update	Ralph Magrish	10 minutes

<i>Informational</i>	Announcements	Chair Bailey, Staff	3 minutes
<i>Informational</i>	General public comment <i>Comments will be limited to 3 minutes per person or organization. Written comments are reviewed by the board prior to the meeting.</i>	Chair Bailey	10 minutes
<i>Informational</i>	Adjournment	Chair Bailey	2 minutes

Next meeting

June 19, 2024, at 9:30 a.m.

Accessibility

Anyone needing assistance due to a disability can contact Melissa Stiles at least 48 hours ahead of the meeting at pdab@dcbs.oregon.gov or 971-374-3724. advance.

How to provide testimony to the board

The Prescription Drug Affordability Board welcomes people to provide testimony. Testimony is when a person sends a letter to the board or signs up to speak during a board meeting. There are two types of testimony: general testimony is about any topic not related to the affordability review; affordability review testimony is about the drugs the board will consider during the affordability review process taking place between May and November 2024. There are two ways to provide testimony: oral or written. Oral testimony is speaking to the board during the public comment portion of the agenda. Written testimony is sending comments in writing to the board. Written comments will be posted to the PDAB website.

General testimony

- **Oral:** To speak during a board meeting about any topic not related to the affordability review, please submit the PDAB public comment form no later than 24 hours before the PDAB meeting.
- **Written:** to provide written comments about any topic not related to the affordability review, please submit the [PDAB public comment form](#) with attachments no later than 72 hours before the PDAB meeting.

Drug affordability review testimony

- **Oral:** To speak during a board meeting about a drug under reviewed by the board, please submit the [PDAB public comment form](#) no later than 24 hours before the PDAB meeting.
- **Written:** to provide written comments about a drug under review by the board, please submit the [PDAB public comment form](#) with attachments by the deadlines posted on the [affordability review web page](#). Written comments specific to drugs under review and submitted by the deadlines below will be included in the affordability review drug reports that are posted one week before the meeting. However, written comments specific to drugs under review may be submitted up until 72 hours before the November board meeting.

Open and closed sessions

All board meetings except executive sessions are open to the public. Pursuant to ORS 192.660, executive sessions are closed, with the exception of news media and staff. No final actions will be taken in the executive session. When action is necessary, the board will return to an open session.